1Department of Urology, Kyungpook National University School of Medicine, Daegu, Korea
2Biomedical Research Institute, Kyungpook National University Hospital, Daegu, Korea
3Department of Pathology, Kyungpook National University School of Medicine, Daegu, Korea
Copyright © 2018 Yeungnam University College of Medicine
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Variable | Value |
---|---|
Median follow-up period (mon) | 71 (66-78)a) |
Mean patient age (yr) | 68.1±7.5 |
Mean BMI (kg/m2) | 24.0±2.4 |
Mean PSA (ng/mL) | 16.0±14.8 |
Mean prostate volume (cc) | 36.6±16.1 |
Neoadjuvant hormonal therapy | 6 (4.7) |
D'Amico risk | |
Low | 30 (23.4) |
Intermediate | 47 (38.8) |
High | 51 (39.8) |
Variable | Value |
---|---|
Median follow-up period (mon) | 71 (66-78) |
Mean patient age (yr) | 68.1±7.5 |
Mean BMI (kg/m2) | 24.0±2.4 |
Mean PSA (ng/mL) | 16.0±14.8 |
Mean prostate volume (cc) | 36.6±16.1 |
Neoadjuvant hormonal therapy | 6 (4.7) |
D'Amico risk | |
Low | 30 (23.4) |
Intermediate | 47 (38.8) |
High | 51 (39.8) |
Variable | Value |
---|---|
Pathological T stage | |
T2 | 64 (50.0) |
T3a | 42 (32.8) |
T3b | 22 (17.2) |
Pathologic Gleason score | |
6 | 24 (18.7) |
7 | 70 (54.7) |
8-10 | 34 (26.6) |
Pathological nodal stage | |
N0 | 125 (97.7) |
N1 | 3 (2.3) |
Lymphovascular invasion | |
No | 112 (87.5) |
Yes | 16 (12.5) |
Surgical margin status | |
Negative | 63 (49.2) |
Positive | 65 (50.8) |
T2 | 20/64 (31.3) |
T3a | 30/42 (71.4) |
T3b | 15/22 (68.2) |
BCR | 43 (33.6) |
Median BCR-free survival, months | 65.9 (0.4-88.0) |
Distant metastasis | 4 (3.1) |
Adjuvant Androgen deprivation therapy | |
No | 70 (54.7) |
Yes | 58 (45.3) |
Duration, months | 13.73 (3-55) |
Salvage radiotherapy | 4 (3.1) |
Chemotherapy | 4 (3.1) |
Mortality | |
Overall death | 3 (2.3) |
Death from PCa | 2 (1.6) |
Variable | BCR (-) (n=85, 66.4%) | BCR (+) (n=43, 33.6%) | p-value |
---|---|---|---|
Age (yr) | 69.0±8.0 | 67.4±6.6 | 0.275 |
BMI (kg/m2) | 24.1±2.5 | 24.0±2.1 | 0.589 |
D’Amico risk | 0.003 | ||
Low | 22 (25.9) | 8 (18.6) | |
Intermediate | 38 (44.7) | 9 (20.9) | |
High | 25 (29.4) | 26 (60.5) | |
Preoperative PSA (ng/mL) | 13.4±9.8 | 20.6±20.1 | 0.013 |
Prostate volume on TRUS (cc) | 37.3±17.5 | 35.1±12.7 | 0.522 |
Pathological stage | 0.001 | ||
T2 | 47 (55.3) | 17 (39.5) | |
T3a | 31 (36.5) | 11 (25.6) | |
T3b | 7 (8.2) | 15 (34.9) | |
Pathologic Gleason score | 0.005 | ||
6 | 21 (24.7) | 3 (7.0) | |
7 | 48 (56.5) | 22 (51.2) | |
8-10 | 16 (18.8) | 18 (41.9) | |
Lymphovascular invasion (+) | 7 (8.2) | 9 (20.9) | 0.041 |
Surgical margin status (+) | 40 (47.1) | 25 (58.1) | 0.159 |
Variable | HR | 95% CI |
p-value | |
---|---|---|---|---|
Lower | Higher | |||
<BCR> | ||||
Preoperative PSA (ng/mL) | 1.030 | 0.982 | 1.079 | 0.223 |
D’Amico risk classification | ||||
Low | 1 | |||
Intermediate | 0.495 | 0.184 | 1.331 | 0.164 |
High | 1.322 | 0.544 | 3.215 | 0.538 |
Pathological stage | ||||
T2 | 1 | |||
T3a | 0.558 | 0.244 | 1.277 | 0.167 |
T3b | 1.998 | 0.925 | 4.317 | 0.078 |
Pathologic Gleason score | ||||
6 | 1 | |||
7 | 3.163 | 0.875 | 11.433 | 0.079 |
8-10 | 4.180 | 1.020 | 17.121 | 0.047 |
Lymphovascular invasion(no vs. yes) | 1.555 | 0.710 | 3.404 | 0.270 |
Univariate analysis |
Multivariate analysis |
|||||
---|---|---|---|---|---|---|
Continence (n=95, 74.2%) | Incontinence (n=33, 25.8%) | p-value | HR | 95% CI | p-value | |
Age (yr) | 67.6±7.7 | 70.7±6.5 | 0.033 | 0.965 | 0.919-1.014 | 0.158 |
BMI (kg/m2) | 24.0±2.6 | 24.0±1.8 | 0.940 | 0.917 | 0.634-1.328 | 0.647 |
ECOG | 0.372 | 0.057 | ||||
0 | 34 (35.8) | 9 (27.3) | 1 | |||
1 | 61 (64.2) | 24 (72.7) | 4.196 | 0.957-18.393 | ||
D’Amico risk classification | 0.913 | |||||
Low | 23 (24.2) | 7 (21.2) | 1 | |||
Intermediate | 34 (35.8) | 13 (39.4) | 0.479 | 0.027-8.585 | 0.617 | |
High | 38 (40.0) | 13 (39.4) | 0.147 | 0.016-1.352 | 0.090 | |
Preoperative PSA (ng/mL) | 15.1±12.2 | 18.4±20.1 | 0.299 | 0.936 | 0.863-1.014 | 0.107 |
Neoadjuvant hormonal therapy | 0.177 | 0.998 | ||||
No | 92 (90.9) | 30 (96.8) | ||||
Yes | 3 (9.1) | 3 (3.2) | ||||
Prostate volume on TRUS | 36.9±17.2 | 35.8±12.4 | 0.153 | 1.032 | 0.977-1.090 | 0.256 |
Pathological T stage | 0.350 | 0.927 | ||||
T2 | 49 (51.6) | 15 (45.5) | ||||
T3a | 28 (29.5) | 14 (42.4) | ||||
T3b | 18 (18.9) | 4 (12.1) | ||||
Pathological GS | 0.890 | |||||
6 | 17 (17.9) | 7 (21.9) | 1 | |||
7 | 53 (55.8) | 17 (51.5) | 2.741 | 0.039-191.541 | 0.642 | |
8-10 | 25 (26.3) | 9 (27.3) | 9.493 | 0.524-171.946 | 0.128 | |
ADT | 0.231 | 0.247 | ||||
No | 49 (51.6) | 21 (63.6) | 1 | |||
Yes | 46 (48.4) | 12 (36.4) | 3.526 | 0.418-29.773 |
Values are presented as mean±standard deviation or number (%). BMI, body mass index; PSA, prostate-specific antigen. Mean (minimum-maximum).
Values are presented as mean (minimum-maximum) or number (%). BCR, biochemical recurrence; PCa, prostate cancer.
Values are presented as mean±standard deviation or number (%). BMI, body mass index; PSA, prostate-specific antigen; TRUS, transrectal ultrasound.
HR, hazard ratio; CI, confidence interval.
Values are presented as mean±standard deviation or number (%). BMI, body mass index; ECOG, ECOG performance status; PSA, prostate-specific antigen; TRUS, transrectal ultrasound; GS, Gleason score; ADT, androgen deprivation therapy.